Stratasys Ltd. Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

Equity (Tables)

Equity (Tables)

12 Months Ended

Dec. 31, 2021

Stockholders' Equity Note [Abstract]

Schedule of stock option activity

		Number of Options			Weighted Average Exercise Price
Options outstanding as of December 31, 2020		2,102,529		$	28.06
Granted		84,326			13.00
Exercised		(399,911	)		20.14
Forfeited		(54,576	)		37.72
Options outstanding as of December 31, 2021		1,732,368		$	28.85
Options exercisable as of December 31, 2021		1,376,409		$	31.99

Schedule of Stock Options Outstanding

								Options Outstanding												Options Exercisable
									Outstanding				Weighted- Average				Weighted-				Exercisable			Weighted-
									options at				Remaining				Average				options at			Average
Range of									December 31,				Contractual				Exercise				December 31,			Exercise
Exercise Prices									2021				Life in Years				Price				2021			Price
$	0.76		-	$	19.66				799,417				6.71			$	17.87				481,418		$	19.32
$	19.96		-	$	23.41				445,930				5.80				21.72				445,930			21.72
$	24.66		-	$	91.56				476,942				3.22				52.28				438,982			54.64
$	103.36		-	$	120.51				10,079				2.80				104.84				10,079			104.84
									1,732,368				5.49			$	28.85				1,376,409		$	31.99

Aggregate intrinsic value (U.S. $ in thousands)								$	6,529											$	3,725

Schedule of Stock Option Assumptions

		2021	2020
Risk-free interest rate		0.4%-1.3%	0.4%-1.8%
Expected option term (years)		5.0-5.1	5.0-5.1
Expected share price volatility		52.8%-58.7%	52.5%-52.8%
Dividend yield		-	-
Weighted average grant date fair value		$14.99	$8.09

Schedule of RSUs and PSUs activity

			Number of RSUs and PSUs				Weighted Average Grant Date Fair Value
Unvested RSUs outstanding as of December 31, 2020			2,801,116			$	21.08
Granted			1,378,782				33.66
Vested			(729,565	)			21.71
Forfeited			(367,535	)			22.71
Unvested RSUs outstanding as of December 31, 2021			3,082,798			$	26.36

Schedule of stock-based compensation expense

			2021				2020				2019
		(U.S. $ in thousands)
Cost of revenues		$	3,093			$	1,771			$	1,848
Research and development, net			6,564				6,102				5,167
Selling, general and administrative			21,320				12,331				13,549
Total stock-based compensation expenses		$	30,977			$	20,204			$	20,564

Schedule of accumulated other comprehensive loss

		Year ended December 31, 2021
			Net unrealized gain (loss) on cash flow hedges					Foreign currency translation adjustments					Total
		U.S. $ in thousands
Balance as of January 1, 2021		$	(1,673	)			$	(7,173	)			$	(8,846	)
Other comprehensive loss before reclassifications			3,668					(2,603	)				1,065
Amounts reclassified from accumulated other comprehensive loss			(423	)				(567	)				(990	)
Other comprehensive income (loss), net of tax			3,245					(3,170	)				75
Balance as of December 31, 2021		$	1,572				$	10,343				$	(8,771	)

		Year ended December 31, 2020
			Net unrealized gain (loss) on cash flow hedges					Foreign currency translation adjustments					Total
		U.S. $ in thousands
Balance as of January 1, 2020		$	(10	)			$	(7,706	)			$	(7,716	)
Other comprehensive loss before reclassifications			(1,024	)				533					(490	)
Amounts reclassified from accumulated other comprehensive loss			(639	)				-					(639	)
Other comprehensive income (loss)			(1,663	)				533					(1,130	)
Balance as of December 31, 2020		$	(1,673	)			$	(7,173	)			$	(8,846	)

		Year ended December 31, 2019
			Net unrealized gain (loss) on cash flow hedges					Foreign currency translation adjustments					Total
		U.S. $ in thousands
Balance as of January 1, 2019		$	(627	)			$	(7,126	)			$	(7,753	)
Other comprehensive loss before reclassifications			1,548					(580	)				968
Amounts reclassified from accumulated other comprehensive loss			(931	)				-					(931	)
Other comprehensive income (loss)			617					(580	)				37
Balance as of December 31, 2019		$	(10	)			$	(7,706	)			$	(7,716	)